

Presented by



In collaboration with



Malaysian
Oncological
Society

OFFICIALLY LICENSED
BEST OF ASCO®
ASCO20 Virtual

5th & 6th December 2020
Malaysia










Best of ASCO 2020, Malaysia has been awarded
16 CPD points by Academy of Medicine of Malaysia





Scientific Agenda

Scientific Programme

DAY-1 5 th December 2020 11:55 - 18:55 Malaysian Time				
Time	Session Type	Speaker Name	Moderator	Title of Presentation
11:55	Presidential Address	 Dr. Muhammad Azrif		Inaugural address
12:00 - 14:00 Pre-Conference Workshop - From Bench-to-Bedside: The Role of Biomarkers in Immunotherapy				
12:00 - 12:05	MSD MasterClass	 Dr. Azura Rozila Ahmad		Welcome & Opening Remarks
12:05 - 12:40	MSD MasterClass with Q&A	 Dr. Pathmanathan Rajadurai	 Dr. Azura Rozila Ahmad	Biomarker on the horizon & science behind the biomarker
12:40 - 13:15	MSD MasterClass with Q&A	 Dr. Nuttapon Ngamphaiboon	 Dr. Azura Rozila Ahmad	Value of PD-L1 testing for H&N cancer IO treatment
13:15 - 13:50	MSD MasterClass with Q&A	 Dr. Azura Rozila Ahmad		Value of PD-L1 testing for NSCLC cancer IO treatment
13:50 - 13:55	MSD MasterClass	 Dr. Azura Rozila Ahmad		Question & Answer Session
13:55 - 14:00	MSD MasterClass	 Dr. Azura Rozila Ahmad		Closing Remarks
14:05 - 14:45 Session 1 - Breast Cancer - Local / Regional / Adjuvant				
14:05 - 14:10	Presentation	 Dr. Seema Khan		A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
14:10 - 14:15	Presentation	 Dr. Jennifer Leong		Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (TDM1) pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high- risk HER2-positive early breast cancer (EBC).
14:15 - 14:20	Presentation	 Dr. Cynthia Ma		ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2- negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106.
14:20 - 14:25	Presentation	 Dr. Ishita Laroia		MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.
14:30 - 14:45	Panel Discussion & Q&A	 Dr. Cynthia Ma  Dr. Jennifer Leong  Dr. Ishita Laroia	 Dr. Aqilah Othman	

14:50 - 15:30		Session 2 - Breast Cancer - Metastatic	
14:50 - 14:55	Presentation	 Dr. Javier Cortes	Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo + chemotherapy in recurrent inoperable or metastatic triple-negative breast cancer
14:55 - 15:00	Presentation	 Dr. Hafizah Zaharah	A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
15:00 - 15:05	Presentation	 Dr. Mastura Md Yusof	MONARCH 2: subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer
15:05 - 15:10	Presentation	 Dr. Vaishnavi Jeyasingam	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer
Quick Quiz 1			
15:15 - 15:30	Panel Discussion & Q&A	 Dr. Javier Cortes  Dr. Mastura Md Yusof  Dr. Vaishnavi Jeyasingam	 Dr. Ang Soo Fan
15:35 - 15:55	Sponsored Session by Zuellig Pharma	 Dr. Antonio Lumbart Cussac	CDK4/6 Inhibitor in the Management of Metastatic Breast Cancer: Are they all the same?
15:55 - 16:10		Exhibition Tour Break	
16:10 - 16:20		Session 3 - Melanoma / Skin Cancers	
16:10 - 16:15	Presentation	 Dr. Amod Sarnaik	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
16:15 - 16:20	Presentation	 Dr. Shivam Verma	Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
16:25 - 16:35		Session 4 - Cancer Prevention, Risk Reduction and Genetics	
16:25 - 16:30	Presentation	 Dr. Ho Gwo Fuang	Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counselling during online testing for breast and ovarian cancer genetic risk.
16:30 - 16:35	Presentation	 Dr. Aqilah Binti Othman	Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).

16:40 - 16:45		Session 5 - Sarcoma	
16:40 - 16:45	Presentation	 Dr. Hadi B. Jalil	Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).
Quick Quiz 2			
16:50 - 17:00		Session 6 - Central Nervous System Tumors	
16:50 - 16:55	Presentation	 Dr. Jennifer Leong	Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C.
16:55 - 17:00	Presentation	 Dr. Hafizah Zaharah	Long-Term Analysis of the WHO-Defined Molecular Subgroups of High-Risk Grade II Gliomas Treated with Radiation and Temozolomide on NRG Oncology/RTOG 0424
17:05 - 17:15		Session 7 - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	
17:05 - 17:10	Presentation	 Dr. Lim Yueh Ni	Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial
17:10 - 17:15	Presentation	 Dr. Chandan Das	Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial
Quick Quiz 3			
17:15 - 17:30		Exhibition Tour Break	
17:30 - 17:40		Session 8 - Gastrointestinal Cancer—Colorectal and Anal	
17:30 - 17:35	Presentation	 Dr. Salvatore Siena	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
17:35 - 17:40	Presentation	 Dr. Alberto F. Sobrero	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
17:45 - 18:15		Session 9 - Gastrointestinal Cancer—Gastroesophageal, Pancreatic and Hepatobiliary	
17:45 - 17:50	Presentation	 Dr. Tan Chih Kiang	Efficacy, Tolerability and Biologic Activity of a Novel Regimen of Tremelimumab (T) in Combination with Durvalumab (D) for Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC).
17:50 - 17:55	Presentation	 Dr. Junie Khoo YY	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study
Quick Quiz 4			
17:55 - 18:15		Exhibition Tour Break	

18:15 - 18:35		Session 10 - Genitourinary Cancer—Kidney and Bladder	
18:15 - 18:20	Presentation	 Dr. Adlinda Alip	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
18:20 - 18:25	Presentation	 Dr. Maha H.A. Hussain	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
18:25 - 18:30	Presentation	 Dr. Wong Yoke Fui	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
18:30 - 18:35	Presentation	 Dr. Michael Atkins	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
18:40 - 18:55		Quiz Session 1	



DAY - 2 | 6th December 2020 | 10:55 - 17:30 | Malaysian Time

Time	Session Type	Speaker Name	Moderator	Title of Presentation
10:55	Presidential Address	 Dr. Muhammad Azrif		Welcome Address
11:00 - 11:40 Session 11 - Genitourinary Cancer—Prostate, Testicular and Penile				
11:00 - 11:05	Presentation	 Dr. Teng Aik Ong		Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
11:05 - 11:10	Presentation	 Dr. Aditya P. Sharma		Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
11:10 - 11:15	Presentation	 Dr. Kalpesh Parmar		Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
11:15 - 11:20	Presentation	 Dr. Cheah Soon Keat		Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Quick Quiz 1				
11:25 - 11:40	Panel Discussion & Q&A	   	 Dr. Junie Khoo YY	
11:45 - 12:20 Session 12 - Lung Cancer - Non-Small Cell Metastatic				
11:45 - 11:50	Presentation	 Dr. Navneet Singh		Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)
11:50 - 11:55	Presentation	 Dr. Tan Chih Kiang		Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
11:55 - 12:00	Presentation	 Dr. Makoto Maemondo		Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
Quick Quiz 2				

12:05 - 12:20	Panel Discussion & Q&A	 Dr. Tan Chih Kiang  Dr. Navneet Singh	 Dr. Liam Chong Kin
12:25 - 13:00 Session 13 - Gynecologic Cancer			
12:25 - 12:30	Presentation	 Dr. Hafizah Zaharah Binti Ahmad	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
12:30 - 12:35	Presentation	 Dr. Rozita Abdu Malik	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
12:35 - 12:40	Presentation	 Dr. Bhavana Rai	Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer. Final analysis of AGO DESKTOP III/ENGOT-ov20
12:40 - 12:45	Presentation	 Dr. Aashima Arora	Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.
Quick Quiz 3			
12:50 - 13:05	Panel Discussion & Q&A	 Dr. Aashima Arora  Dr. Bhavana Rai	 Dr. S. C. Saha
13:10 - 13:40 Session 14 - Head and Neck Cancer			
13:10 - 13:15	Presentation	 Dr. Wan Zamaniah Wan Ishak	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
13:15 - 13:20	Presentation	 Dr. Naomi Kiyota	Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).
13:20 - 13:25	Presentation	 Dr. Bhumsuk Keam	Randomized phase II study of axitinib versus observation in patients with recurrent or metastatic adenoid cystic carcinoma.
13:25 - 13:30	Presentation	 Dr. Robert Ferris	Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311)
Quick Quiz 4			
13:35 - 13:45	Panel Discussion & Q&A	 Dr. Naomi Kiyota  Dr. Wan Zamaniah Wan Ishak	 Dr. Divya Khosla
13:45 - 14:00 Exhibition Tour Break			

14:00 - 14:35		Session 15 - Hematologic Malignancies - Leukemia, MDS and Allotransplant	
14:00 - 14:05	Presentation	 Dr. Hany Haqimi Wan Hanafi	Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
14:05 - 14:10	Presentation	 Dr. Hany Haqimi Wan Hanafi	Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
14:10 - 14:15	Presentation	 Dr. Hany Haqimi Wan Hanafi	Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
14:15 - 14:20	Presentation	 Dr. Hany Haqimi Wan Hanafi	Updated Results from Phase I Dose-Escalation Study of AMG 330, a Bispecific T-Cell Engager Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
14:25 - 14:35	Panel Discussion & Q&A	 Dr. Hany Haqimi Wan Hanafi	 Dr. Azlan Husin
14:40 - 15:10		Session 16 - Hematologic Malignancies - Lymphoma and CLL	
14:40 - 14:45	Presentation	 Dr. John G. Kuruvilla	Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
14:45 - 14:50	Presentation	 Dr. Ganesh Kasinathan	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).
14:50 - 14:55	Presentation	 Dr. Ganesh Kasinathan	Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
14:55 - 15:00	Presentation	 Dr. Ganesh Kasinathan	A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome.
15:05 - 15:10	Panel Discussion & Q&A	 Dr. Ganesh Kasinathan	 Dr. Lau Ngee Siang
15:15 - 15:55		Session 17 - Hematologic Malignancies-Plasma Cell Dyscrasia	
15:15 - 15:20	Presentation	 Dr. Shaji Kumar	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
15:20 - 15:25	Presentation	 Dr. Nur Adila Bt Anuar	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

15:25 - 15:30	Presentation	 Dr. Nur Adila Bt Anuar	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
15:30 - 15:35	Presentation	 Dr. Nur Adila Bt Anuar	Phase I Study of Teclistamab, a Humanized B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (R/R MM)
15:40 - 15:55	Panel Discussion & Q&A	 Dr. Nur Adila Bt Anuar	 Dr. Haris Abdul Rahman
15:55 - 16:10 Exhibition Tour Break			
16:10 - 17:10 Session 18 - Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other			
16:10 - 16:15	Presentation	 Dr. Roy S. Herbst	Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
16:15 - 16:20	Presentation	 Dr. Tang Weng Heng	Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.
16:20 - 16:25	Presentation	 Dr. Hye Ryun Kim	Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
16:25 - 16:30	Presentation	 Dr. Yi-Long Wu	Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
16:30 - 16:45	Panel Discussion & Q&A	 Dr. Roy S. Herbst	 Dr. Jennifer Leong
16:50 - 17:05 Quiz Session 2			
17:10 Onwards Valedictory & Awards' Declaration			

OFFICIALLY LICENSED
BEST OF ASCO®
ASCO20 Virtual


LEADERBOARD & AWARDS

SPONSORED BY


ASCO[®]

LEADERBOARD!

How to achieve points on Leaderboard ?



EXCITING PRIZES TO BE WON VIA LEADERBOARD



1st & 2nd Position

Digital Access to
ASCO20 Videos and Slides



3rd & 4th Position

Digital Access to IO Symposium
Videos and Slides



5th, 6th & 7th Position

Digital Access to
2020 Educational Book

**Winners will be declared in the end of the Conference (Approx. 17:00 – 17:30)
on Day 2, 6th December, 2020.**


ASK YOUR BEST QUESTIONS AND WIN EXCITING AWARDS

SPONSORED BY
ASCO[®]

MR./MS. CROSS EXAMINER

Mr./Ms. Cross Examiner will be awarded to delegates who will drop most relevant questions in the Q&A box during each session.

ASK RELEVANT QUESTIONS DURING THE CONFERENCE AND
STAND A CHANCE TO WIN AWARDS SPONSORED BY ASCO



1st Position

Digital Access to
ASCO20 Videos and Slides



2nd Position

Digital Access to IO Symposium
Videos and Slides



3rd Position

Digital Access to 2020 Educational Book

**Winners will be declared in the end of the Conference (Approx. 17:00 – 17:30)
on Day 2, 6th December, 2020.**

Thank you Partners

Patron Partner



Diamond Partner



Gold Partner



Exhibitor



MAKING MORE TOMORROWS POSSIBLE FOR PATIENTS



Almost



mNSCLC patients have the
chance to survive 5 years^{1,2}

Actor portrayal. Not an actual patient



Scan the QR code to access the
Selected Safety Information

References: 1. Garon EB, et al. 5-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. *J Clin Oncol* 37. Presented at ASCO 2019. 2. Brahmer JR, et al. KEYNOTE-024 5-year OS update: first-line pembrolizumab vs platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score ≥ 50%. Presented at Virtual ESMO 2020.

For Healthcare Professionals Only

Before prescribing KEYTRUDA®, please read the Local Product Circular.

Copyright© 2020 Merck Sharp & Dohme (M) Sdn. Bhd., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.
MY-KEY-00431 Nov/2020

KEYTRUDA®
(pembrolizumab) Injection 100 mg

Lilly



ZUELLIG
PHARMA

Today impacts tomorrow's choices

How do you maximize survival for your EGFR M+ NSCLC patients?



**Boehringer
Ingelheim**

Full prescribing information is available upon request
For Healthcare Professionals only

Boehringer Ingelheim (Malaysia) Sdn. Bhd. Company No: 118601000402 (149391-H)
Suite 15-5 Level 15, Wisma UOA Damansara II, No 6 Jalan Changkat Semantan,
Damansara Heights, 50490 Kuala Lumpur.
Tel: +603 2092 0088 Fax: 603 2095 2818

EM-MY-100154, November 2020



once-daily tablets
Zytiga[®]
abiraterone acetate

Time for life



Erleada[®]
(apalutamide) tablets
It's TIME to push back!

janssen

PHARMACEUTICAL COMPANIES

OF *Johnson & Johnson*



OFFICIALLY LICENSED
BEST OF ASCO®
ASCO20 Virtual

5th & 6th December 2020
Malaysia



Presented by



Support Desk

90306 95668 | 81306 06116 | 88006 91399 | 86555 64901

www.bestofoncology.org

